Suppr超能文献

瑞米唑仑与丙泊酚用于危重症和非危重症患者复杂手术全身麻醉的随机试验荟萃分析

Remimazolam Versus Propofol in General Anesthesia of Complex Surgery in Critical and Non-Critical Patients: Meta-Analysis of Randomized Trials.

作者信息

Muñoz-Carrillo José Luis, Rodríguez-Cortes Natalie, Lévano Sandra Trujillo, Moran-Mariños Cristian, Barboza Joshuan J

机构信息

Laboratorio de Inmunología, Centro Universitario de los Lagos, Universidad de Guadalajara, Lagos de Moreno, Jalisco 47460, PC, Mexico.

Facultad de Medicina, Universidad El Bosque, Bogotá 110121, PC, Colombia.

出版信息

J Clin Med. 2024 Dec 20;13(24):7791. doi: 10.3390/jcm13247791.

Abstract

: To compare the efficacy and safety of remimazolam with propofol in general anesthesia in adult patients. : A systematic search in Pubmed, Scopus, Web of Science, and Embase was performed. Patients undergoing complex surgery who were critically ill or non-critically ill were included. The risk of bias (RoB) 2.0 tool was applied. Random-effects models using the inverse variance method were applied for all meta-analyses. : Nine randomized controlled trials were included (patients taking remimazolam, n = 678; propofol, n = 454). Remimazolam compared to propofol is likely to produce a large decrease in intraoperative hypotension (RR 0.62, 95% CI 0.50 to 0.76, I2 = 63%, n = 9, CoE moderate certainty), incidence of respiratory depression (RR 0.28, 95% CI 0.09 to 0. 82, I2 = 0%, n = 3; CoE moderate certainty), injection site pain (RR 0.14, 95% CI 0.02 to 0.94, I2 = 21%, n = 4; CoE moderate certainty), and may produce little or no difference in bradycardia (RR 0.61, 95% CI 0.36 to 1.06, I2 = 0%, n = 4; CoE moderate certainty). : In patients undergoing complex surgery who are critically ill or non-critically ill, remimazolam, compared with propofol, is likely to produce a large decrease in intraoperative hypotension, incidence of respiratory depression, and injection site pain, but little or no difference in bradycardia is possible.

摘要

比较瑞米唑仑与丙泊酚用于成人患者全身麻醉的疗效和安全性。

在PubMed、Scopus、Web of Science和Embase数据库中进行系统检索。纳入接受复杂手术的危重症或非危重症患者。应用偏倚风险(RoB)2.0工具。所有荟萃分析均采用逆方差法的随机效应模型。

纳入9项随机对照试验(使用瑞米唑仑的患者,n = 678;使用丙泊酚的患者,n = 454)。与丙泊酚相比,瑞米唑仑可能会使术中低血压大幅降低(风险比[RR] 0.62,95%置信区间[CI] 0.50至0.76,I² = 63%,n = 9,证据确定性中等)、呼吸抑制发生率降低(RR 0.28,95% CI 0.09至0.82,I² = 0%,n = 3;证据确定性中等)、注射部位疼痛发生率降低(RR 0.14,95% CI 0.02至0.94,I² = 21%,n = 4;证据确定性中等),并且可能在心动过缓方面几乎没有差异(RR 0.61,95% CI 0.36至1.06,I² = 0%,n = 4;证据确定性中等)。

在接受复杂手术的危重症或非危重症患者中,与丙泊酚相比,瑞米唑仑可能会使术中低血压、呼吸抑制发生率和注射部位疼痛大幅降低,但在心动过缓方面可能几乎没有差异。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/79d7/11728358/c781c84e48db/jcm-13-07791-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验